Calzada V - Search Results

1

177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma.

Camacho X, Calzada V, Fernandez M, Alonso O, Chammas R, Riva E, Gambini JP, Cabral P. Camacho X, et al. Among authors: calzada v. Curr Radiopharm. 2017;10(1):21-28. doi: 10.2174/1874471009666161010155246. Curr Radiopharm. 2017. PMID: 27748184

2

Synthesis of 99mTc-nimotuzumab with tricarbonyl ion: in vitro and in vivo studies.

Garcia MF, Camacho X, Calzada V, Fernandez M, Porcal W, Alonso O, Gambini JP, Cabral P. Garcia MF, et al. Among authors: calzada v. Curr Radiopharm. 2012 Jan;5(1):59-64. doi: 10.2174/1874471011205010059. Curr Radiopharm. 2012. PMID: 22074480

3

A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab.

Calzada V, Zhang X, Fernandez M, Diaz-Miqueli A, Iznaga-Escobar N, Deutscher SL, Balter H, Quinn TP, Cabral P. Calzada V, et al. Curr Radiopharm. 2012 Oct;5(4):318-24. doi: 10.2174/1874471011205040318. Curr Radiopharm. 2012. PMID: 22280117

4

Synthesis and evaluation of (99m)Tc chelate-conjugated bevacizumab.

Camacho X, García MF, Calzada V, Fernández M, Porcal W, Alonso O, Gambini JP, Cabral P. Camacho X, et al. Among authors: calzada v. Curr Radiopharm. 2013 Mar;6(1):12-9. doi: 10.2174/1874471011306010003. Curr Radiopharm. 2013. PMID: 23035645

5

[(99m)Tc(CO)(3)]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model.

Camacho X, García MF, Calzada V, Fernández M, Chabalgoity JA, Moreno M, Barbosa de Aguiar R, Alonso O, Gambini JP, Chammas R, Cabral P. Camacho X, et al. Among authors: calzada v. Oncology. 2013;84(4):200-9. doi: 10.1159/000338961. Epub 2013 Jan 15. Oncology. 2013. PMID: 23328435

6

Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.

Calzada V, Garcia F, Fernández M, Porcal W, Quinn T, Alonso O, Gambini JP, Cabral P. Calzada V, et al. World J Nucl Med. 2013 Jan;12(1):27-32. doi: 10.4103/1450-1147.113953. World J Nucl Med. 2013. PMID: 23961253 Free PMC article.

7

Microwave-assisted synthesis of HYNIC protected analogue for 99mTc labeled antibody.

García MF, Calzada V, Camacho X, Goicochea E, Gambini JP, Quinn TP, Porcal W, Cabral P. García MF, et al. Among authors: calzada v. Curr Radiopharm. 2014;7(2):84-90. doi: 10.2174/1874471007666141128160449. Curr Radiopharm. 2014. PMID: 25429778 Review.

8

Fab(nimotuzumab)-HYNIC-99mTc: Antibody Fragmentation for Molecular Imaging Agents.

Calzada V, García MF, Alonso-Martínez LM, Camachoc X, Goicochea E, Fernández M, Castillo AX, Díaz-Miqueli A, Iznaga-Escobar N, Montaña RL, Alonso O, Gambini JP, Cabral P. Calzada V, et al. Anticancer Agents Med Chem. 2016;16(9):1184-9. doi: 10.2174/1871520616666160310143828. Anticancer Agents Med Chem. 2016. PMID: 26961312

9

Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept.

Calzada V, Moreno M, Newton J, González J, Fernández M, Gambini JP, Ibarra M, Chabalgoity A, Deutscher S, Quinn T, Cabral P, Cerecetto H. Calzada V, et al. Bioorg Med Chem. 2017 Feb 1;25(3):1163-1171. doi: 10.1016/j.bmc.2016.12.026. Epub 2016 Dec 24. Bioorg Med Chem. 2017. PMID: 28089349

10

Derivatizations of Sgc8-c aptamer to prepare metallic radiopharmaceuticals as imaging diagnostic agents: Syntheses, isolations, and physicochemical characterizations.

Sicco E, Báez J, Margenat J, García F, Ibarra M, Cabral P, Moreno M, Cerecetto H, Calzada V. Sicco E, et al. Among authors: calzada v. Chem Biol Drug Des. 2018 Mar;91(3):747-755. doi: 10.1111/cbdd.13135. Epub 2017 Nov 24. Chem Biol Drug Des. 2018. PMID: 29080264

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page